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Abstract
Background: Previous studies regarding the prognosis of patients infected with MRSA isolates characterized by a high 
minimum inhibitory concentration (MIC) for vancomycin have generally used a commercial Etest. Little research has 
been conducted on determining the vancomycin susceptibility of MRSA using a reference microdilution. Additionally, 
there is discordance between the MIC result from an Etest and the value determined using the reference microdilution 
method.
Methods: Using a reference microdilution method, we determined the MIC of vancomycin for isolates from 123 
consecutive patients with nosocomial MRSA bacteremia. The clinical features and outcome for these patients were 
recorded and the MRSA isolates were genotyped.
Results: Among the 123 non-duplicated isolates, 21.1% had a MIC = 2 mg/L, 76.4% had a MIC = 1 mg/L and 2.4% had 
MIC = 0.5 mg/L. Patients with MRSA bacteremia in the ICU or those who had been hospitalized for a long time were 
more likely to be infected with strains of high vancomycin MIC MRSA (MIC = 2 mg/L; p < 0.05). Cox regression analysis 
demonstrated that the high MIC group had a significantly higher 30-day mortality than the low MIC group (HR: 2.39; 
95% CI: 1.20-4.79; p = 0.014). Multivariate analyses indicated that the presence of high MIC isolates, pneumonia, post-
cardiothoracic surgery and a high Charlson comorbidity index were all independent predictors of a 30-day mortality. 
Genotyping of these high vancomycin MIC isolates demonstrated that SCCmec III, spa type037, was the predominant 
strain (> 80%). The rates of resistance to trimethoprim/sulfamethoxazole, gentamicin, levofloxacin, rifampin and 
tetracycline were also higher in the high MIC group than in the isolates belonging to low MIC group (p < 0.05).
Conclusions: In a high vancomycin MIC group in Taiwan, SCCmec III, spa type t037, was the predominant strain of 
MRSA identified. Patients with MRSA bacteremia in the ICU or who had prolonged hospitalization were more likely to 
be infected with S. aureus strains with high vancomycin MICs. The mortality rate was higher among patients infected 
with these strains compared to patients infected with low MIC strains.
Background
In 2004, Sakoulas et al. observed that a significant risk for
vancomycin treatment failure in MRSA bacteremia is
first indicated by increasing vancomycin MICs that are
well within the susceptible range [1]. Most of the studies
examining the impact of high vancomycin MIC in
patients with MRSA bacteremia published after the Sak-
oulas et al. report have used the commercial E test and
found similar results [2-4]. However, a recent study, using
multivariate analysis, demonstrated that there was no dif-
ference in mortality between high MIC and low MIC
patient groups [5]. There were discordant MIC results
between different susceptibility methods [6-8]. Further-
more, there has been little research examining the use of
reference microdilution as a method of vancomycin sus-
ceptibility determination [9].
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Additionally, a previous genotype study in the U.S.
showed that SCCmec II was the genotype that was most
predictive of high vancomycin MIC isolates [10]. In Tai-
wan, the molecular epidemiology of isolates from
patients with MRSA bacteremia is distinct [11]. We do
not know if the high vancomycin MIC isolates from
patients in T aiwan have a similar genotype as in those
seen in patients in the U.S.
Therefore, we collected bacteria from consecutive
patients with nosocomial MRSA bacteremia and, using
the Clinical and Laboratory Standards Institute (CLSI)
reference broth microdilution, determined vancomycin
MICs. We examined the association of infection with
high MIC strains (MIC = 2 mg/L) and mortality and gen-
otyped the isolates.
Methods
This study was approved by the local institutional ethics
review board (expedited review). The Institutional
Review Board waived the need for informed consent
from participants because the study involved very mini-
mal risk to the subjects, did not include intentional
deception and did not involve sensitive populations or
topics; this waiver does not adversely affect the rights and
welfare of the subjects. Throughout the one-year study
period (January 1 to December 31, 2006), we collected
clinical data from 123 non-duplicated, consecutive noso-
comial MRSA bacteremia patients from the National Tai-
wan University Hospital in Taipei, Taiwan. During the
study period, vancomycin and teicoplanin were the rec-
ommended antibiotics for treating MRSA bacteremia at
our institutions. All patients were evaluated using a struc-
tured recording form. The clinical course of infection and
the infection focus were evaluated and recorded accord-
ing to information supplied by primary care physicians
and medical records.
Identification of the infection focus was based on clini-
cal, bacteriological and radiological investigations, and
was defined according to criteria established by the Cen-
ters for Disease Control and Prevention [12]. We assessed
patient survival rates 30 days after the diagnosis of bacte-
remia by follow-up at outpatient clinics or by telephone
for patients who did not come to the outpatient clinics.
The vancomycin MIC of the 123 MRSA isolates was
determined by broth microdilution, as described by the
CLSI in 2005 [13]. In vitro testing of these isolates was
performed in a blinded fashion without knowledge of any
clinical outcomes. Isolates with vancomycin MIC = 2 mg/
L were designated the "high MIC" group; those with MIC
= 1 mg/L or 0.5 mg/L were considered to be the "low
MIC" group. The susceptibility of the S. aureus isolates to
levofloxacin, erythromycin, tetracycline, trimethoprim/
sulfamethoxazole, gentamicin, clindamycin and rifampin
was determined according to standard microbiological
methods [13]. The presence of the SCCmec elements (I-
V) was determined by previously described methods
[14,15]. The polymorphic X-region of the protein A gene
(spa) was analyzed as previously described [16].
Percentages were used for all categorical variables. For
univariate analysis, we compared the high MIC and low
MIC groups with a χ2 test or Fisher's exact test. We used
multivariate logistic regression analyses to determine
associations between potential risk factors and the pres-
ence of isolates with a high or low vancomycin MIC. The
cumulative survival time after the first MRSA positive
blood culture was calculated using the Kaplan-Meier
method. The difference in cumulative survival of patients
infected with high or low vancomycin MIC S. aureus was
determined using the log-rank test. The effect of high
MIC isolates on patient outcome was evaluated using a
multivariate Cox proportional hazards regression model
and a logistic regression model adjusted for age, sex and
underlying comorbidities. Data were analyzed using SPSS
software for Windows (Release 15.0; SPSS, Chicago, IL).
Results
Among the 123 non-duplicated isolates, 21.1% had a MIC
= 2 mg/L, 76.4% had a MIC = 1 mg/L and 2.4% had a MIC
= 0.5 mg/L (Table 1). Univariate analysis indicated that
patients with MRSA bacteremia who were in the ICU (p
= 0.028) or who had been hospitalized for a long time, i.e.,
> 60 days, (p = 0.022) were more likely to be infected with
MRSA strains with a high vancomycin MIC (MIC = 2
mg/L). Multivariate analysis indicated that this effect
remained after adjusting for sex, age and the presence of
underlying disease. There were no other significant
demographic differences between the high MIC and low
MIC groups (Table 1). The infection syndrome, treat-
ment and outcome are shown in Table 2.
The relationship between MIC and Day 14 and Day 30
mortality is shown in Figure 1. Additionally, we used Cox
regression and logistic regression to evaluate the relation-
ship between vancomycin MIC and mortality. Univariate
analyses indicated that the presence of high MIC isolates,
malignancy, a high Charlson comorbidity index, bedrid-
den status and admission to the ICU were predictors of
mortality after 30 days (p < 0.05) (Table 3). Variables with
a p-value < 0.20 in the univariate analyses were included
in the subsequent multivariate Cox proportional hazards
regression model. Multivariate analyses in combination
with Cox regression indicated that the presence of high
MIC isolates, pneumonia, history of cardiothoracic sur-
gery and a high Charlson comorbidity index were inde-
pendent predictors of mortality after 30 days (p < 0.05).
Patients infected with high MIC isolates had a greater 30-
day mortality rate than patients infected with low MIC
isolates, as indicated by univariate analysis (hazard ratio
(HR) = 2.20; 95% confidence interval (CI): 1.13-4.27; p =Wang et al. BMC Infectious Diseases 2010, 10:159
http://www.biomedcentral.com/1471-2334/10/159
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Table 1: Demographic characteristics of nosocomial bacteremia patients infected with high MIC or low MIC MRSA
Characteristic Vancomycin MIC < 2 N = 97 
Number of patients (%)
Vancomycin MIC = 2 N = 26 
Number of patients (%)
p-valuea p-valueb; OR (95% CI)
Elderly (>65 years old) 66 (68.0) 13 (50.0) 0.088
Age 70.32 ± 14.1 63.6 ± 18.0 0.250
Sex: male 68 (70.1) 14 (53.8) 0.118 0.04; 0.33 (0.11-0.95)
Diabetes 70 (72.2) 17 (65.4) 0.500
Cancer 30 (30.9) 11(43.2) 0.349
Congestive heart failure 14 (14.4) 4(15.4) 1.000
End stage renal disease 10 (10.3) 4 (15.4) 0.492
Liver cirrhosis 11 (11.3) 3 (11.5) 1.000
Cerebrovascular disease 24 (24.7) 3 (11.5) 0.188
Bedridden 24 (24.7) 7 (26.9) 0.804
Recent surgery 24 (24.7) 3 (11.5) 0.188 0.018; 0.15 (0.03-0.73)
Recent cardio-thoracic surgery 13 (13.4) 1 (3.8) 0.297
Hospitalization days before bacteremia 22.6 ± 10.1 23.7 ± 8.0 0.207
ICU admission before bacteremia 40 (41.2) 17 (65.4) 0.028 0.005; 4.83 (1.61-14.50)
Hospitalization > 2 months before 
bactermia
17 (17.5) 10 (38.5) 0.022 0.011; 4.56 (1.41-14.73)
Hospitalization > 1 month before 
bacteremia
41 (42.3) 15 (57.7) 0.187
a: p-value calculated using a χ2 test or Fisher's exact test
b: p-value as determined by logistic regression.
Table 2: Infection syndrome, treatment and outcome of nosocomial bacteremia in patients infected with high MIC MRSA 
or low MIC MRSA
Syndrome & treatment Vancomycin MIC < 2 N = 97 
Number of patients (%)
Vancomycin MIC = 2 N = 26 
Number of patients (%)
p-valuea
Syndrome
Primary bacteremia 18 (18.6) 5 (19.2) 0.938
Pneumonia 32 (33.0) 9 (34.6) 0.876
Catheter related infection 40 (41.2) 12 (46.2) 0.652
Prosthesis 6(6.2) 0 (0) 0.341
Infective endocarditis 6 (6.2) 0 (0) 0.341
Treatment
Empirical glycopeptide use within 48 hours 71 (73.2) 19 (73.1) 1.000
Vancomycin trough level (mg/L) 14.9 ± 7.6 (n = 47) 13.5 ± 4.9 (n = 12) 0.176
Vancomycin trough level > 10 mg/L in first week 34 (72.3) 9 (75.0) 1.000
With a DNR orderb 26 (26.8) 11 (42.3) 0.151
Outcome
2 week death 14 (14.4) 8 (30.8) 0.081
30 days death 27 (27.8) 13 (50.0) 0.057
a: p-value calculated using a χ2 test or Fisher's exact test
b: Do not resuscitateWang et al. BMC Infectious Diseases 2010, 10:159
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0.021) and multivariate Cox regression analysis (HR =
2.39; 95% CI: 1.20-4.79; p  = 0.014). By using stepwise
logistic regression, the presence of high MIC isolates,
cancer, a high Charlson comorbidity index and a history
of cardiothoracic surgery were shown to be independent
predictors of mortality after 30 days (p < 0.05) (Table 4).
The 30-day cumulative survival was 72.2% for patients
infected with low MIC isolates and was 50% for patients
infected with high MIC isolates (Figure 2). A log-rank test
indicated that this difference was statistically significant
(p = 0.0232). The Cox regression survival curves for
patients infected with high MIC or low MIC isolates are
shown in Figure 3. Analysis of the distribution of the
SCCmec genotype and spa genotype in the high and low
MIC groups indicated that most of the high-MIC isolates
had the genotype SCCmec III, spa type t037 (Table 5).
The high MIC group also displayed a higher resistance
rate to other antibiotics (Table 5).
Discussion
Our results show that patients infected with isolates of
MRSA with a high vancomycin MIC, as determined by
standard broth microdilution methods, tend to have
higher mortality. This is in agreement with previous stud-
ies using Etest as the method of susceptibility determina-
tion, which displayed differing success rates (23-45%)
with vancomycin treatment of patients infected with high
MIC and low MIC isolates [1-5,9]. Our survival analysis
indicated that patients infected with high MIC isolates
had a 16% higher mortality after 14 days and a 22% higher
mortality after 30 days compared to patients infected
with low MIC isolates. The poor clinical outcome of
patients infected with high MIC isolates remained after
adjusting for confounding variables.
Contrary to the results reported by Musta et al., our
study showed patients infected with MRSA with high
vancomycin MIC had a higher mortality rate, as assessed
by multivariate analyses, compared to patients infected
with low vancomycin MIC isolates. The reason for these
differences may be explained by the use of a different
MIC test (Etest vs. microdilution) and different SCCmec
genotypes, i.e., SCCmec III, t037. In a previous report,
vancomycin MICs generated using the Etest were consis-
tently a one- to two-fold dilution higher than MICs deter-
mined using the CLSI broth dilution method [6,7]. We
think our cohort contained more patients infected with
high vancomycin MIC isolates than the Musta et al.
cohort; thus, their observed difference may have been
more significant if their study had involved more patients
infected with high vancomycin MIC S. aureus.
The higher mortality rate of patients infected with high
MIC isolates may be explained by an inadequate AUC/
MIC ratio, delayed bacterial killing in the high MIC group
[1-5,9], and/or the existence of strains of heteroresistant
Figure 1 Mortality in different vancomycin MIC group. The rela-
tionship between vancomycin MIC and 14- and 30-days mortality
Table 3: Univariate and multivariate analysis of risk factors associated with mortality of patients with nosocomial MRSA 
bacteremia using Cox regression
Characteristic Univariate 
HR
95% CI p-value Multivariate 
HR
95% CI p-value
High vancomycin MIC 2.20 1.13-4.27 0.021 2.39 1.20-4.79 0.014
Malignancy 2.73 1.45-5.11 0.002 2.09 0.99-4.43 0.053
Pneumonia 1.74 0.92-3.27 0.088 2.27 1.17-4.40 0.016
Cardiothoracic surgery 1.86 0.82-4.20 0.139 4.38 1.74-11.04 0.002
Charlson score 1.27 1.10-1.46 0.001 1.24 1.07-1.45 0.005
Endocarditis 2.24 2.24-6.31 0.126
Bedridden 2.63 1.03-6.71 0.044
Cerebrovascular disease 2.06 0.81-5.27 0.131
ICU admission 2.05 1.07-3.90 0.029
Note: Variables with a p < 0.2 in the univariate analyses were included in the subsequent multivariate Cox proportional hazards regression 
model.Wang et al. BMC Infectious Diseases 2010, 10:159
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vancomycin-intermediate  S. aureus [17]. The higher
mortality rate in high MIC group may also be associated
w i t h  o t h e r  c o v a r i a t e s  t h a t  w e r e  n o t  m e a s u r e d  i n  t h i s
study such as severity of acute illness (i.e.APACHE II
score) or do not resuscitate orders.
In our isolates from the high MIC group, the most com-
mon (> 80%) genotype was SCCmec III, spa type t037.
MRSA sequence type (ST) 239, spa type t037, SCCmec
III, is now the most prevalent nosocomial strain in many
Asian countries [11,18-20] and has also been detected in
26 countries outside of Asia [21]. In a study from Singa-
pore and Hong Kong, MRSA ST239 (SCCmec  III/spa
type t037) was found to comprise a higher proportion of
the high vancomycin MIC isolates than other SCCmec
type strains [22,23]. The distribution of staphylococcal
cassette chromosome mec types and correlation with
comorbidity and infection type in our patients with
MRSA bacteremia has been described in another study
[24]. The high vancomycin MIC and the high resistance
rate to other antibiotics associated with this major clone
is a therapeutic challenge for clinicians.
Broth microdilution is a standard CLSI method for
determining MICs, but this technique is time consuming
and labour intensive. The limitation of this study is that it
is a retrospective, single center study in Taiwan and the
local MRSA vancomycin MIC distribution pattern in Tai-
wan may not be applicable to other countries. Clonal
transmission among these MRSA isolates is also possible.
Additionally, other confounding factors for the mortality
analysis such as more do not resuscitate order in high
MIC group than low MIC group may also exist.
Table 4: Univariate and multivariate analyses of risk factors associated with mortality in patients with nosocomial MRSA 
bacteremia using logistic regression
Characteristic Univariate OR 95% CI p-value Multivariate ORa 95% CI p-value
High vancomycin MIC 2.59 1.07-6.30 0.035 3.76 1.34-10.54 0.012
Malignancy 3.48 1.57-7.74 0.002 3.06 1.15-8.17 0.025
Pneumonia 1.82 0.83-3.99 0.137
Cardiothoracic surgery 2.30 0.75-7.09 0.146 5.66 1.52-21.12 0.010
Charlson score 1.27 1.06-1.52 0.009 1.25 1.01-1.55 0.045
Endocarditis 4.50 0.79-25.69 0.09
Bedridden 3.19 1.12-9.08 0.03
Cerebrovascular disease 2.52 0.88-7.26 .086
ICU admission 2.27 1.05-4.91 .037
a: Covariates having a p < 0.2 were included in the stepwise regression, and covariates with a higher p-value were discarded.
Figure 2 Kaplan-Meier survival curves of high-MIC and low-MIC 
group. Kaplan-Meier survival curves of patients with nosocomial MRSA 
bacteremia who were infected with high-MIC isolates (lower line) or 
low-MIC isolates (upper line). Log-rank test: p = 0.0232
Figure 3 Cox regression survival curves of high-MIC and low-MIC 
group. Cox regression survival curves of patients with nosocomial 
MRSA bacteremia who were infected with high-MIC isolates (lower 
line) or low-MIC isolates (upper line)Wang et al. BMC Infectious Diseases 2010, 10:159
http://www.biomedcentral.com/1471-2334/10/159
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Conclusions
In conclusion, using a microdilution method, our study
shows that patients with MRSA bacteremia who are in
the ICU or who have been hospitalized for a long time
may be infected with strains of high vancomycin MICs
(MIC = 2 mg/L ). Patients infected with high-MIC strains
h a d  h i g h e r  m o r t a l i t y  t h a n  p a t i e n t s  i n f e c t e d  w i t h  l o w -
MIC strains.
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